Sugi Predict

Sugi Predict / Targets / PDGFRA

PDGFRA

Platelet-derived growth factor receptor alpha · P16234 · PDGFRA on Sugi Atlas →

190,776 patent compounds predicted against PDGFRA, 133,560 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9820 SCHEMBL9820 1.00 15/20
SCHEMBL9782 SCHEMBL9782 1.00 14/20
SCHEMBL9677 SCHEMBL9677 1.00 13/20
SCHEMBL9837 SCHEMBL9837 1.00 13/20
SCHEMBL97567 SCHEMBL97567 0.73 13/20
SCHEMBL1522 SCHEMBL1522 1.00 12/20
SCHEMBL9666 SCHEMBL9666 1.00 12/20
SCHEMBL9763 SCHEMBL9763 1.00 12/20
SCHEMBL1430 SCHEMBL1430 0.88 12/20
SCHEMBL9565 SCHEMBL9565 1.00 11/20
SCHEMBL9642 SCHEMBL9642 1.00 11/20
SCHEMBL10208 SCHEMBL10208 0.82 11/20
SCHEMBL9838 SCHEMBL9838 0.79 11/20
SCHEMBL9971 SCHEMBL9971 0.57 11/20
SCHEMBL9197 SCHEMBL9197 1.00 10/20
SCHEMBL9862 SCHEMBL9862 0.79 10/20
SCHEMBL1442 SCHEMBL1442 0.78 10/20
SCHEMBL1365 SCHEMBL1365 1.00 9/20
SCHEMBL1762 SCHEMBL1762 1.00 9/20
SCHEMBL9338 SCHEMBL9338 1.00 9/20

Clinical trials — most relevant to PDGFRA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST PHASE3COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients PHASE2COMPLETED
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) PHASE2RECRUITING
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy PHASE2COMPLETED
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations PHASE2WITHDRAWN
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer PHASE2COMPLETED
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors PHASE2COMPLETED
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment PHASE2COMPLETED
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer PHASE2COMPLETED
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma PHASE2COMPLETED
Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib PHASE1/PHASE2COMPLETED
Effect of Imatinib in Advance Liver Fibrosis Patients PHASE1/PHASE2UNKNOWN
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma PHASE1RECRUITING
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration PHASE1COMPLETED
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) PHASE1ACTIVE_NOT_RECRUITING
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors PHASE1WITHDRAWN
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma PHASE1COMPLETED
Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma PHASE1UNKNOWN
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function PHASE1COMPLETED
Platelet-Rich Plasma for Partial Rotator Cuff Tears nanNOT_YET_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion nanACTIVE_NOT_RECRUITING
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors nanRECRUITING
Platelet Rich Plasma for Treatment of Facial Photoaging: A Double-blind, Randomized, Split-face Study nanUNKNOWN
Platelet Rich Plasma for Uterine Scar nanRECRUITING
Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma nanCOMPLETED
Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDGFRA binder may also engage these)

ProteinNameSimilarity
P26619 — 1.000 P26619 →
P26618 — 1.000 P26618 →
Q8AXC7 — 1.000 Q8AXC7 →
Q9PUF6 — 1.000 Q9PUF6 →
P43481 — 1.000 P43481 →
Q28317 — 1.000 Q28317 →
Q2HWD6 — 1.000 Q2HWD6 →
Q91909 — 1.000 Q91909 →
P20786 — 1.000 P20786 →
Q76II0 — 0.999 Q76II0 →
Q8JFR5 — 0.999 Q8JFR5 →
Q28889 — 0.999 Q28889 →
Q9I8N6 — 0.999 Q9I8N6 →
Q9DE49 — 0.998 Q9DE49 →
Q08156 — 0.997 Q08156 →
P52583 — 0.997 P52583 →
P05532 — 0.997 P05532 →
P79749 — 0.997 P79749 →
Q5GIT4 — 0.996 Q5GIT4 →
Q00495 — 0.996 Q00495 →
P79750 — 0.995 P79750 →
KIT Mast/stem cell growth factor receptor Kit 0.995 landscape →
O97799 — 0.995 O97799 →
KDR Vascular endothelial growth factor receptor 2 0.994 landscape →
O08775 — 0.993 O08775 →
P79701 — 0.993 P79701 →
P35918 — 0.993 P35918 →
Q26614 — 0.993 Q26614 →
Q8UVR8 — 0.993 Q8UVR8 →
Q60629 — 0.992 Q60629 →